Omidubicel is a nicotinamide modified unrelated allogeneic hematopoietic progenitor cell therapy derived from cord blood.

Incyte announced that a phase 3 program evaluating INCA033989 in ET patients with all types of CALR mutations is expected to begin in mid-2026.

At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.

If the products were acquired through the Novo Nordisk Patient Assistance Program, the product is genuine and not counterfeit.

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

(HealthDay News) — One dose of bivalent or nonavalent human papillomavirus (HPV) vaccine is noninferior to 2 doses for protecting against HPV16 and HPV18 infection, according to a study published ...

Investigators sought compare the efficacy and safety of a chemo-free approach to TKI + chemotherapy in newly-diagnosed adult Ph+ ALL.

In the phase 3 COBRA trial, researchers sought to compare the efficacy of KRd to VRd in newly diagnosed multiple myeloma patients regardless of cytogenic risk or transplant eligibility.

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Except for public health advocates (72% opposed), more than 60% of each speaker type supported approval. Patients and family members with drug experience had the highest support for approval (99%), 12 ...

Guidelines expanded to include self-collection for HPV testing and revised guidance for exiting cervical cancer screening ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...